top of page
AvantGuard News
Search
AvantGuard Awarded $2.65 Million in NIH Grants to Advance Next-Generation Antimicrobial Technologies
AvantGuard Awarded $2.65 Million in NIH Grants to Advance Next-Generation Antimicrobial Technologies
Nov 13
$325K NIH Phase I Grant: Advancing Urinary Catheter Technology with AvantGuard
AvantGuard has been awarded a $325K NIH Phase I Grant for non-coating antimicrobial, anti-host deposition, anti-inflammatory urinary catheters. Catheter-associated urinary tract infection (CAUTI) is the most common type of healthcare-associated infection, however currently there is no effective technology to address the problem. Antimicrobial (anti-biofilm) functionality on the catheter surface is an important field that has gained a lot of attention; however, commercial app
Jun 7, 2023
AvantGuard Secures $2.85 Million in Oversubscribed Seed Round Funding to Accelerate Research and Dev
NEW YORK, May 11, 2023 /PRNewswire/ -- AvantGuard, a fast-growing company in the antimicrobial industry, announced today the successful...
May 11, 2023
AvantGuard Receives $1.7M NIH Grant for AvantGuard247â„¢
AvantGuard, Inc. is pleased to announce a $1.7 million Phase II SBIR award from the National Institutes of Health (NIH) to continue...
Apr 18, 2023
bottom of page